Regeneron Pharmaceuticals

Update in progress

REGN (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines to treat diseases worldwide. Its therapies include EYLEA for various retinal diseases; Dupixent for atopic dermatitis and asthma; Libtayo for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent for heterozygous familial hypercholesterolemia; and Kevzara for rheumatoid arthritis. It partners with Bayer, Alnylam, Intellia, Hansoh, and Tessera. Founded 1988, based in Tarrytown, NY.

Company score

Sentiment: 0.02; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: -0.48; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 1.41; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -1.06; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.03; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.02; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive